Romeu Bes J
Department of Neuropsychiatry, Autonomous University of Barcelona, Spain.
Clin Ther. 1992 Sep-Oct;14(5):672-7.
The subjects, 104 patients who had experienced more than two migraine episodes per month during the previous 6 months, received 60 mg of nicardipine daily for 2 months in an uncontrolled, Phase-IV study. Eighty-nine patients (mean age, 40 years; 16 with and 73 without aura; 60 women) completed the treatment regimen. The patients' blood pressure did not change during treatment. The mean number of migraine attacks was reduced significantly from 6.7 per month during the 3 months before treatment to 4.0 per month during treatment. The number of severe attacks was also reduced significantly. The patients' subjective ratings of the frequency and intensity of the attacks and their need for analgesia were reduced significantly from before to after treatment. Side effects (flushing and shortness of breath) were reported by four patients. It is concluded that nicardipine is safe and effective in the prevention of migraine attacks.
在一项非对照的IV期研究中，104名在过去6个月中每月经历超过两次偏头痛发作的受试者，每天服用60毫克尼卡地平，持续2个月。89名患者（平均年龄40岁；16名有先兆，73名无先兆；60名女性）完成了治疗方案。治疗期间患者血压未发生变化。偏头痛发作的平均次数从治疗前3个月的每月6.7次显著减少至治疗期间的每月4.0次。严重发作次数也显著减少。患者对发作频率和强度以及镇痛需求的主观评分从治疗前到治疗后显著降低。4名患者报告了副作用（脸红和呼吸急促）。结论是尼卡地平在预防偏头痛发作方面安全有效。
